Chronic Myelomonocytic Leukemia
Last Posted: Mar 10, 2023
- DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features.
Palomo Laura, et al. Epigenetics 2017 0 (1) 8-18
- Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.
Patnaik Mrinal M, et al. American journal of hematology 2017 0 (1) 65-73
- Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
Hu Zhihong, et al. Human pathology 2018 0 290-298
- Mutation analysis of therapy-related myeloid neoplasms.
Nishiyama Takahiro, et al. Cancer genetics 2018 0 38-45
- Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
Coltro Giacomo, et al. Leukemia 2019 0 (5) 1407-1421
- Genotypic and phenotypic evolution in a patient with chronic myelomonocytic leukemia.
Geissler Klaus, et al. Leukemia research reports 2019 0 100185
- Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia.
Woo Janghee, et al. Haematologica 2019 0 (3) 652-660
- DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.
Quesada Andrés E, et al. American journal of hematology 2019 0 (7) 757-766
- Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia.
Awada Hassan, et al. Blood advances 2019 0 (3) 339-349
- Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia.
Montalban-Bravo Guillermo, et al. American journal of hematology 2020 0 (2) E50-E53
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2023
- Page last updated:Jun 07, 2023
- Content source: